The plasma lipidome varies with the severity of metabolic dysfunction-associated steatotic liver disease
Plasma lipids hold promise as biomarkers of MASLD stages, whereas plasma PC(36:2) concentrations would be able to distinguish individuals with MASH from those with MASLD without MASH.
Authors
- Ger H. Koek (ORCID: https://orcid.org/0000-0002-7863-392X)
- Saskia W. C. van Mil (ORCID: https://orcid.org/0000-0002-7850-5012)
- Maarten E. Tushuizen (ORCID: https://orcid.org/0000-0001-6342-9056)
- Aldo Grefhorst (ORCID: https://orcid.org/0000-0003-1761-9494)
- Anne Linde Mak (ORCID: https://orcid.org/0000-0002-2101-161X)
- Joanne Verheij (ORCID: https://orcid.org/0000-0003-1283-630X)
- Adriaan Georgius Holleboom (ORCID: https://orcid.org/0000-0002-2911-2917)
- Ronit Shiri‐Sverdlov (ORCID: https://orcid.org/0000-0002-6736-7814)
- Clément J. F. Heymann
Institutions
- Leiden University (NL)
- Utrecht University (NL)
- Maastricht University Medical Centre (NL)
- University Medical Center Utrecht (NL)
- Maastricht University (NL)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- Lipids in Health and Disease
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s12944-024-02380-x
- Citations
- 4
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.55
Funders
- Amsterdam University Medical Centers